Reminder: Investor Conference Call Today, February 26, 2019; Management to Provide Update
27 February 2019 - 12:47AM
InvestorsHub NewsWire
Reminder: Investor Conference Call Today, February 26, 2019;
Management to Provide Update on Initiatives & Strategic Plans,
Call-in Details
MIRAMAR, FL -- February 26, 2019 -- InvestorsHub NewsWire
-- Generex Biotechnology Corporation (www.generex.com)
(OTCQB: GNBT) (http://www.otcmarkets.com/stock/GNBT/quote) today
announced the following access information for its investor
conference call, to be hosted by President & Chief Executive
Officer Joseph Moscato, and his management team today February 26,
at 11:00 AM Eastern time:
Investors & persons of interest calling into event:
Domestic US/Canada - 1-888-632-3385
Direct Toll / International - 1-785-424-1673
Conference ID - 85014
The purpose of the call is to update investors on the previously
announced and pending acquisitions that offer significant value to
the Generex parent company. Joseph Moscato, Generex President &
Chief Executive Officer, will discuss the company’s financing plans
related to the acquisitions, as well as the strategic focus of
Generex for 2019 and beyond. Topics for discussion include:
- Potential Acquisition of 13 Hospitals as well as Hospital IT
and Management company
- Potential Acquisition of World Class Nutraceutical Company
- Potential Acquisition of Home Delivered Medically Approved
Foods Business for Chronic Care of diabetes, cancer,
cardiovascular, and rheumatoid arthritis patients
- Acquisition of Direct to Patient End to End Pharmacy
Business
- Update on Fuse Medical Acquisition
- Update on Medisource Partners Acquisition
- Update on Pantheon Acquisition
- Update on NuGenerex Immuno-Oncology (NGIO) dividend and Go
Public Strategy
- Acquisition plans for NGIO Merger with Company with Synergistic
Platforms
- NGIO Acquisition of World Class IP
- Discussion of financial and legal issue
About Generex Biotechnology Corp.
Generex Biotechnology is an integrated healthcare holding
company with end-to-end solutions for patient centric care from
rapid diagnosis through delivery of personalized therapies. Generex
is building a new kind of healthcare company that extends beyond
traditional models providing support to physicians in an MSO
network, and ongoing relationships with patients to improve the
patient experience and access to optimal care.
In addition to advancing a legacy portfolio of immune-oncology
assets, medical devices, and diagnostics, the Company is focused on
an acquisition strategy of strategic businesses that complement
existing assets and provide immediate sources of revenue and
working capital. Recent acquisitions include a management services
organization, a network of pharmacies, clinical laboratory, and
medical device companies with new and approved products.
Our newly formed, wholly-owned subsidiary, NuGenerex
Distribution Solutions (NDS), integrates our MSO network with a
pharmacy network, clinical diagnostic lab, durable medical
equipment company (DME-IQ) and dedicated call center.
Cautionary Note Regarding Forward-Looking
Statements
This release and oral statements made from time to time by
Generex representatives in respect of the same subject matter may
contain "forward-looking statements" within the meaning of the
Private Securities Litigation Reform Act of 1995. These statements
can be identified by introductory words such as "expects," "plan,"
"believes," "will," "achieve," "anticipate," "would," "should,"
"subject to" or words of similar meaning, and by the fact that they
do not relate strictly to historical or current facts.
Forward-looking statements frequently are used in discussing
potential product applications, potential collaborations, product
development activities, clinical studies, regulatory submissions
and approvals, and similar operating matters. Many factors may
cause actual results to differ from forward-looking statements,
including inaccurate assumptions and a broad variety of risks and
uncertainties, some of which are known and others of which are not.
Known risks and uncertainties include those identified from time to
time in the reports filed by Generex with the Securities and
Exchange Commission, which should be considered together with any
forward-looking statement. No forward-looking statement is a
guarantee of future results or events, and one should avoid placing
undue reliance on such statements. Generex undertakes no obligation
to update publicly any forward-looking statements, whether as a
result of new information, future events or otherwise.
Generex claims the protection of the safe harbor for
forward-looking statements that is contained in the Private
Securities Litigation Reform Act.
Generex
Contact:
Generex Biotechnology Corporation
Joseph Moscato
646-599-6222
Todd Falls
1-800-391-6755 Extension 222
nvestor@generex.com
Generex Biotechnology (CE) (USOTC:GNBT)
Historical Stock Chart
From Apr 2024 to May 2024
Generex Biotechnology (CE) (USOTC:GNBT)
Historical Stock Chart
From May 2023 to May 2024